tyrosine
kinase
regulate
signaling
pathway
control
cell
growth
proliferation
motility
critical
cellular
process
mutation
tyrosine
kinase
gene
lead
abnormal
kinase
activity
tumor
become
dependent
upon
activity
growth
survival
thus
kinase
attractive
target
drug
example
new
kinase
inhibitor
include
gefitinib
erlotinib
recently
shown
promise
treating
lung
cancer
unfortunately
gefitinib
erlotinib
work
subset
patient
severe
side
effect
albeit
infrequently
researcher
trying
find
way
predict
benefit
therapy
drug
following
work
lynch
et
al
engl
med
paez
et
al
science
william
pao
colleague
previously
shown
epidermal
growth
factor
receptor
egfr
tyrosine
kinase
often
mutated
lung
cancer
tumor
harbor
mutation
sensitive
gefitinib
erlotinib
new
study
focused
signaling
protein
called
kras
function
downstream
many
tyrosine
kinase
including
egfr
kras
gene
also
often
mutated
lung
cancer
cancer
mutation
egfr
kras
gene
find
whether
kras
mutation
could
help
predict
patient
would
respond
gefitinib
erlotinib
researcher
looked
mutation
egfr
kras
gene
tumor
sensitivity
either
drug
known
extended
earlier
finding
egfr
mutation
found
tumor
associated
sensitivity
kinase
inhibitor
found
tumor
mutation
kras
total
nine
refractory
respond
either
drug
result
need
validated
larger
prospective
trial
use
standardized
mutation
detection
technique
confirmed
knowing
mutation
status
egfr
kras
tumor
could
help
physician
decide
patient
receive
gefitinib
erlotinib
inoue
nukiwa
state
perspective
accompanies
article
combining
factor
relate
response
resistance
patient
benefit
treatment
hopefully
identified
undoubtedly
taken
great
step
forward
molecular
therapy
lung
cancer
treatment
